FDA批准首个XIa因子抑制剂用于帮助预防某些高风险成人卒中
正文 · 中文译文
FDA新闻稿 FDA批准首个因子XIa抑制剂,用于帮助预防某些高风险成人卒中 更多新闻公告 即时发布: 2026年11月9日 美国食品药品监督管理局(FDA)今日批准Sunharbo(asundexian)50 mg片剂,这是首个因子XIa(FXIa)抑制剂,用于与抗血小板治疗联合,以降低近期发生轻至中度非心源性缺血性卒中(由并非起源于心脏的血栓所致的卒中)或高风险短暂性脑缺血发作(TIA,常被称为“小卒中”)后成人患者的卒中风险。 “卒中是导致美国残疾和死亡的主要原因之一,幸存者面临再次发生卒中的风险,”FDA药品评价与研究中心心脏病学、血液病学、内分泌学与肾脏病学办公室主任、医学博士、临床研究理学硕士Hylton V. Joffe说。“今日的批准对于寻求卒中二级预防新选择的患者和医疗保健提供者而言是一项有意义的进展。” Sunharbo的有效性在OCEANIC-STROKE研究中得到证实,该研究是一项多中心、随机、双盲、安慰剂对照的3期研究,共纳入12,327名成人。受试者近期发生非心源性栓塞性缺血性卒中(美国国立卫生研究院卒中量表(NIHSS)≤15)或高危短暂性脑缺血发作(TIA),并在症状出现后72小时内随机分配至Sunharbo或安慰剂组。两组均接受抗血小板治疗。在中位治疗14.2个月期间,与安慰剂相比,Sunharbo 50 mg每日一次显著降低缺血性卒中风险26%。 Sunharbo组与安慰剂组的总体大出血发生率相似,但在75岁以上患者及治疗最初90天内,Sunharbo组大出血发生率升高。与安慰剂相比,Sunharbo组胃肠道出血更常见。最常报告的不良反应(在Sunharbo治疗患者中发生率≥3%)为腹泻。 不建议与联合P-糖蛋白(P-gp)和强效CYP3A4诱导剂类药物(如卡马西平)合用,因为这些药物可能降低Sunharbo的疗效。不建议中度或重度肝功能损害患者使用Sunharbo。择期手术或侵入性操作前应至少停用Sunharbo 24小时,急性缺血性卒中溶栓后应至少停用24小时。Sunharbo未被批准用于心房颤动患者的卒中预防。 FDA授予Sunharbo快速通道和优先审评资格。该批准授予了位于新泽西州惠帕尼的拜耳医疗保健制药公司(Bayer HealthCare Pharmaceuticals Inc.)。 媒体: FDA征求意见 202-690-6343 消费者: 888-INFO-FDA FDA是美国卫生与公众服务部下属的一个机构,通过确保人用和兽用药物、疫苗及其他人用生物制品以及医疗器械的安全性、有效性和保障性来保护公众健康。该机构还负责我国食品供应、化妆品、膳食补充剂、辐射发射电子产品以及烟草产品监管的安全与保障。 ### 内容截至: 2026年11月09日 受监管产品 药物 关注FDA 在X上关注@US_FDA 在Facebook上关注FDA 在X上关注@FDAMedia
正文 · 英文原文
FDA News Release FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk More Press Announcements For Immediate Release: November 09, 2026 The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” “Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke,” said Hylton V. Joffe, M.D., MMSc, Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA’s Center for Drug Evaluation and Research. “Today’s approval represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention.” The effectiveness of Sunharbo was demonstrated in the OCEANIC-STROKE study, a multicenter, randomized, double-blind, placebo-controlled phase 3 study that enrolled 12,327 adults. Participants had a recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk TIA and were randomly assigned to Sunharbo or placebo within 72 hours of symptom onset. Both groups also received antiplatelet therapy. Sunharbo 50 mg once daily significantly reduced the risk of ischemic stroke by 26% compared to placebo over a median treatment of 14.2 months. The overall rate of major bleeding was similar between the Sunharbo and placebo groups but was increased with Sunharbo in patients older than 75 years and during the first 90 days of treatment. Gastrointestinal bleeding occurred more commonly with Sunharbo compared to placebo. The most frequently reported adverse reaction (occurring in 3% or greater of Sunharbo-treated patients) was diarrhea. Concomitant use with medicines that are combined P-gp and strong CYP3A4 inducers (such as carbamazepine) is not recommended because these medicines may decrease Sunharbo’s effectiveness. Sunharbo is not recommended in patients with moderate or severe hepatic impairment. Sunharbo should be withheld at least 24 hours before elective surgery or invasive procedures and for at least 24 hours after thrombolysis for acute ischemic stroke. Sunharbo is not approved for stroke prevention in patients with atrial fibrillation. The FDA granted Sunharbo Fast Track and Priority Review designations. The approval was granted to Bayer HealthCare Pharmaceuticals Inc., Whippany, N.J. Media: FDA Request for Comment 202-690-6343 Consumer: 888-INFO-FDA The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. ### Content current as of: 11/09/2026 Regulated Product(s) Drugs Follow FDA Follow @US_FDA on X Follow FDA on Facebook Follow @FDAMedia on X